All In Biotech

Drug Trial Radar · NCT05163041

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 2, 2021

Primary completion

Aug 2026

Study completion Dec 2026

Sponsor

Lead sponsor
BicycleTx LimitedIndustry
Sponsor type
Industry
First posted
Dec 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression. The main goals of the study are to: * Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab * Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab * Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body * Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function

Conditions

  • Advanced Solid Tumor

Interventions

  • BT7480Drug

    Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

  • NivolumabDrug

    Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with treatment emergent adverse events in dose escalation phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 (+/-5) days after the last dose of study drug
  2. Number of patients with treatment emergent adverse events in dose escalation phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until 125 (+/-5) days after the last dose of study drug
  3. Confirmed response rate as measured by overall response rate (ORR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months
  4. Confirmed response rate as measured by clinical benefit rate (CBR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • State University of Iowa

    Iowa City, Iowa

  • Columbia University Irving Medical Center

    New York, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • START Center for Cancer Care

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • The Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.